The American Society of Transplantation Online Transplant Infectious Diseases Library
Full Library 1,578 resources
-
Abstract. Immunotherapy using antibodies to immune checkpoint molecules or targeted chimeric antigen receptor-modified T cells (CAR-T cells) represent dramatic
-
<h2>Summary</h2><p>Cytomegalovirus is one of the most important infections to occur after allogeneic haematopoietic stem cell transplantation (HSCT), and an increasing number of reports indicate that cytomegalovirus is also a potentially important pathogen in patients treated with recently introduced drugs for hematological malignancies. Expert recommendations have been produced by the 2017 European Conference on Infections in Leukaemia (ECIL 7) after a review of the literature on the...
-
The landscape of clinical mycology is constantly changing. New therapies for malignant and autoimmune diseases have led to new risk factors for unusual mycoses. Invasive candidiasis is increasingly caused by non-albicans Candida spp., including C. auris, a multidrug-resistant yeast with the potential for nosocomial transmission that has rapidly spread globally. The use of mould-active antifungal prophylaxis in patients with cancer or transplantation has decreased the incidence of invasive...
-
Solid organ transplantation (SOT) is the best treatment option for end-stage organ disease. Newer immunosuppressive agents have reduced the incidence of graft rejection but have increased the risk of infection, particularly due to the reactivation of latent infections due to opportunistic agents such as Mycobacterium tuberculosis. Active tuberculosis (TB) after SOT is a significant cause of morbidity and mortality. Most cases of posttransplant TB are secondary to reactivation of latent...
-
Make a difference in the field of transplantation by donating to support our cause.
-
Mycobacterium abscessus pulmonary disease is particularly challenging to treat, given its intrinsic drug resistance and limited data to guide management. In thi
-
Background. Whether antibiotic treatment of asymptomatic bacteriuria (AB) can prevent acute graft pyelonephritis (AGP) in kidney transplant (KT) recipients has not been elucidated. Methods. In this multicenter, open-label, nonblinded, prospective, noninferiority, randomized controlled trial, we compared antibiotic treatment with no treatment for AB in KT recipients in the first year after transplantation when urinary catheters had been removed. The primary endpoint was the occurrence of...
-
Objectives Antibiotics for febrile neutropenia (FN) in acute myeloid leukaemia (AML) patients undergoing intensive chemotherapy are usually maintained until neutropenia resolution, because of the risk of uncontrolled sepsis in this vulnerable population. This leads to unnecessarily prolonged antimicrobial therapy. Methods Based on ECIL-4 recommendations, we modified our management strategy and discontinued antibiotics after a pre-established duration in patients treated for a first episode...
-
Fluoroquinolone prophylaxis in neutropenic, hematologic malignancy patients and hematopoietic-transplant recipients is associated with breakthrough bacteremia w
-
BACKGROUND: Isavuconazole was compared to caspofungin followed by oral voriconazole in a Phase 3, randomized, double-blind, multinational clinical trial for the primary treatment of patients with candidemia or invasive candidiasis. METHODS: Adult patients were randomized 1:1 to isavuconazole (200 mg intravenous [IV] three-times-daily [TID] for 2 days, followed by 200 mg IV once-daily [OD]) or caspofungin (70 mg IV OD on day 1, followed by 50 mg IV OD [70 mg in patients > 80 kg]) for a...
-
Background. We provide the results of the first interventional study of cytomegalovirus (CMV)-specific immune monitoring to direct the length of antiviral prophylaxis in lung transplantation (LTx). Methods. Patients (n = 118) at risk of CMV infection were randomized 1:2 to either 5 months or variable length valganciclovir prophylaxis (5–11 mo post-LTx), as determined by the QuantiFERON (QFN)-CMV assay. Patients with a negative QFN-CMV assay (< 0.2 IU/mL) received prolonged...
-
Find out why people with health problems or who take medicines that weaken the body’s ability to fight germs and sickness are more likely to get a foodborne illness.
-
Find out why people with health problems or who take medicines that weaken the body’s ability to fight germs and sickness are more likely to get a foodborne illness.
-
BACKGROUND: Progressive multifocal leukoencephalopathy (PML) is an opportunistic brain infection that is caused by the JC virus and is typically fatal unless immune function can be restored. Programmed cell death protein 1 (PD-1) is a negative regulator of the immune response that may contribute to impaired viral clearance. Whether PD-1 blockade with pembrolizumab could reinvigorate anti-JC virus immune activity in patients with PML was unknown. METHODS: We administered pembrolizumab at a...
-
HCV-Positive Organ Donors In patients without hepatitis C virus infection who received a heart or lung from HCV-infected donors, 4 weeks of antiviral treatment initiated after surgery rendered all 35 recipients who had completed 6 months of follow-up free of HCV infection despite early signs of infection in 96% of the recipients within hours after surgery.
-
Standardized consensus definitions for resistant and refractory cytomegalovirus (CMV) infections and diseases in transplant recipients were developed by the CMV
-
AbstractBackground. Transplant recipients are an immunologically vulnerable patient group and are at elevated risk of Clostridioides difficile infection (CDI)
Filter by our tag
GUIDELINES
- AASLD Guidelines (9)
- AST Guidelines 2019 (44)
- ASTCT Guidelines (14)
- ECIL Guidelines (20)
- ESCMID Guidelines (25)
- IDSA Guidelines (45)
- ISHLT Guidelines (12)
- TTS Guidelines (2)
- WikiGuidelines (3)
TEXTBOOKS
CORE CURRICULUM
- INTRO LVAD AND MCSS (4)
- INTRO MALIGNANT HEME, HSCT, CAR-T (10)
- INTRO SOLID ORGAN TRANSPLANT (20)
- ORGANISMS (41)
-
SYNDROMES
(16)
- CNS (2)
- Diarrhea (3)
- Neutropenic Fever (2)
- Pneumonia (7)
- UTI (2)
ORGANISMS
-
BACTERIA
(160)
- C. difficile (25)
- Legionella (1)
- MDR GNR (37)
- MRSA (7)
- Mycoplasma and Ureaplasma (11)
- Nocardia (11)
- Non-tuberculous Mycobacteria (27)
- Syphilis (6)
- Tuberculosis (35)
- VRE (8)
-
FUNGI
(218)
- Aspergillus (57)
- Candida (41)
- Cryptococcus (29)
- Dimorphic mycoses (42)
- Mucormycosis (34)
- Pneumocystis (39)
- Rarer Fungi (23)
-
PARASITES AND PROTOZOA
(44)
- Chagas (10)
- Protozoa (12)
- Strongyloides (14)
- Toxoplasmosis (12)
-
VIRUSES
(415)
- Adenovirus (17)
- Arboviruses (7)
-
CMV
(121)
- Cell-Mediated Immunity Assays (11)
- Clinical (55)
- Cytotoxic T-Lymphocytes (1)
- Epidemiology and Risk Factors (15)
- Letermovir (26)
- Maribavir (17)
- Preemptive Therapy (7)
-
COVID-19
(45)
- Diagnosis (3)
- Fungal superinfection (2)
- GUIDELINES (9)
- Infection Prevention (3)
- Positive Donors (6)
- Positive Recipients (5)
- Treatments (18)
- Vaccination (8)
- Hepatitis A (2)
- Hepatitis B (27)
- Hepatitis C (31)
- Hepatitis D (5)
- Hepatitis E (5)
- HHV-6 (24)
- HHV-8 (4)
- HIV (31)
- HPV (5)
- HSV (4)
- Influenza (17)
- Measles (22)
- Mpox (6)
- Norovirus (8)
- Parvovirus B19 (3)
- Polyomaviruses (32)
- Respiratory Viruses (32)
- RSV (18)
- VZV (17)
- WNV (2)
DIAGNOSTICS
- Advanced Diagnostics (23)
- Fungal diagnostics (41)
- Nuclear Medicine (7)
- Parasites (3)
- Procalcitonin (1)
- Viral diagnostics (1)
DRUGS AND THERAPIES
- Antibiotics (12)
- Antifungals (66)
- Antivirals (10)
- Cytotoxic T-lymphocyte therapy (8)
- Fecal Microbiota Transplantation (12)
- Phage therapy (4)
- Stewardship (57)
PREVENTION
- Infection Control (8)
- Safe Living (22)
- Travel (10)
- Vaccination (40)
SYNDROMES AND CONDITIONS
- Cirrhotics (12)
- CNS (3)
- Cytopenias (2)
- Diarrhea (13)
- Endovascular infections (12)
- Osteomyelitis and Diabetic Foot Infection (3)
- Pneumonia (11)
- Surgical Infections (3)
- UTI (32)
SOLID ORGANS AND MCSS
- Donor (43)
- Heart (14)
- Immunosuppression (14)
- Intestinal (2)
- Kidney (32)
- Liver (53)
- Lung (70)
- LVAD (30)
- Pancreas (5)
- PEDIATRIC (43)
- Recipient (5)
- Total Artificial Heart (1)
- Vascular Composite Allograft (2)
- Xenotransplantation (3)
HEME-ONC AND CELLULAR THERAPIES
- Biologics (45)
- BMT Basics (4)
- BMT Guidelines (14)
- BMT Noninfectious (10)
- BMT-specific ID (71)
- CAR-T (22)
- CAR-T Noninfectious (6)
- GVHD (6)
- Heme malignancies (4)
- Heme-onc prophylaxis (23)
- Neutropenia (40)
- PEDIATRIC (33)
- PTLD (24)
- TK inhibitors (12)
TRANSPLANT ID TRAINING
- AST (4)
- Career Development (2)
- Fungal (4)
- Training program (7)
PATIENT EDUCATION
- COVID-19 (13)
- Food (13)
- Hygiene (7)
- Mpox (5)
- Outdoor activities (3)
- PATIENT INFORMATION SHEETS (16)
- Pets (6)
- Safer living (22)
- Selected Infections (10)
- TB (10)
- Travel (6)
- Water safety (7)
- Workplace safety (3)
JOURNAL CLUB
- 2024 (2)